History

Humanin was first reported in 2001 by Hashimoto and colleagues in the Nishimoto group at Keio University School of Medicine in Tokyo (PNAS 2001; PMID 11371646). It emerged from a functional cDNA screen of an occipital brain region relatively spared in Alzheimer's disease, selected for clones that rescued neurons from death induced by familial-AD genes and amyloid-beta. It was the first known mitochondrial-derived peptide — a 24-amino-acid sequence (MAPRGFSCLLLLTSEIDLPVKRRA) encoded within the mitochondrial 16S rRNA gene rather than the cell nucleus. Subsequent work characterized its anti-apoptotic, cytoprotective signaling, and human therapeutic use remains entirely investigational.

Humanin is one of the more scientifically intriguing peptides in the “longevity” corner of the gray market: it’s the first mitochondrial-derived peptide ever found, it has a plausible cytoprotective mechanism, and its blood levels fall with age. But as of mid-2026, the human evidence that injecting it does anything useful — or that it is even safe — is essentially absent. Everything compelling about humanin comes from cells and animals.

What it is

Humanin is a 24-amino-acid peptide (sequence MAPRGFSCLLLLTSEIDLPVKRRA) encoded not by nuclear DNA but by a short reading frame inside the mitochondrial 16S rRNA gene (MT-RNR2). It was discovered in 2001 by the Nishimoto group at Keio University and was the first identified member of a small family of mitochondrial-derived peptides — a group that also includes MOTS-c. Its proposed mechanisms, drawn almost entirely from cell and animal models, are cytoprotective and anti-apoptotic: it interacts with BCL-2-family proteins (notably BAX), binds IGFBP-3, signals through a trimeric CNTFR/WSX-1/gp130 receptor to activate JAK/STAT3, and switches on ERK1/2 and Akt. In vitro it reduces apoptosis driven by oxidative stress and serum starvation. Native humanin has a very short circulating half-life, so most preclinical work uses HNG (the S14G analog), a more potent and more stable synthetic version. Circulating humanin declines with age in people — but that is an observational biomarker correlation, not evidence that supplementing it helps anything.

The claims

Marketing and clinic copy pitch humanin as a longevity, neuroprotective, and “cellular repair” peptide — claims of protecting brain cells, slowing cognitive aging, improving metabolic health, and extending healthspan. The narrative leans heavily on the real observations that humanin is cytoprotective in the lab and that its levels drop with age, with the implied leap that injecting it reverses or delays age-related decline in humans.

What the evidence actually shows

The preclinical signals are real and reasonably consistent, but the human data are purely observational. Nobody in the published literature has been given humanin as a drug.

Cognitive aging (Yen et al., Scientific Reports 2018): The interventional part was in mice — HNG injected into middle-aged and aged mice improved maze and rotarod performance. The human portion was strictly observational: a mitochondrial SNP (rs2854128) was linked to roughly 14% lower circulating humanin and to accelerated cognitive aging in the Health and Retirement Study cohort (more pronounced in African-American participants). No human received humanin.
Lifespan/healthspan (Yen et al., Aging 2020): Overexpression extended lifespan in C. elegans (via daf-16/FOXO), and midlife treatment improved metabolic measures in mice, with supporting data from rhesus macaques and naked mole-rats. The human data are correlational only — for example, higher humanin in centenarians’ offspring and lower CSF humanin in Alzheimer’s. No human intervention.
Cardiac (Qin et al., Am J Physiol Heart Circ Physiol 2018): HNG reduced age-related myocardial fibrosis and apoptosis — mice only.
Neuroprotection and amyloid toxicity: a robust in vitro and rodent literature, with no human confirmation.

There is no completed or published Phase 1, 2, or 3 trial of humanin or HNG given to people as a therapy, and no registered interventional ClinicalTrials.gov study of administered humanin could be found. The closest human study is observational/exercise: Gidlund et al. found that resistance training raised endogenous humanin in men with impaired glucose metabolism — which is the body making more of its own humanin, not a trial of injecting it. The mechanism is interesting and the animal signals are consistent, but the human clinical evidence base is effectively nonexistent. Any longevity, nootropic, or recovery claim for injected humanin in people is unsupported by human trials.

Legal and regulatory status

Humanin is not approved by the FDA or any comparable regulator for any indication, and it is not a dietary supplement. Material sold online is research-grade/gray-market — unapproved and unregulated, with no guarantee of identity, purity, or dose.

On anti-doping: humanin is not listed by name on the WADA 2026 Prohibited List. That is not the same as “allowed.” WADA’s S2 class (Peptide Hormones, Growth Factors, Related Substances and Mimetics) is open-ended and non-exhaustive, and a cytoprotective signaling peptide marketed for performance or recovery could plausibly be argued into it — as well as into the S0 “Non-Approved Substances” catch-all, since humanin has no regulatory approval for human use. The 2026 List also newly added cell components such as nuclei and organelles (including mitochondria and ribosomes) to the M3 gene/cell-doping prohibition; that provision targets transfer of organelles and cell components rather than this peptide itself, but it signals WADA’s growing scrutiny of mitochondrial methods. (For reference, SARMs fall under S1.2 and metabolic modulators like AICAR under S4.4 — neither applies to humanin, which is a peptide.) Athletes should treat humanin as high-risk and likely prohibited under S0/S2 and seek a formal ruling before going near it.

Safety

Human safety is essentially uncharacterized. No completed or published human safety (Phase 1) study could be verified, so there is no controlled human safety data at any dose. Vendor or clinic copy claiming a “favorable safety profile with no serious adverse events at clinical doses” is internally contradictory — it coexists with the fact that no Phase 1 has been completed — and is not supported by published human trial data; disregard it.

Two further concerns are worth naming. First, product-quality risk is significant: research-grade and gray-market peptides carry real purity, sterility, endotoxin, and mislabeling problems independent of the molecule itself. Second, there is a theoretical, mechanism-based concern: humanin’s core action is anti-apoptotic and pro-survival. Chronically blunting programmed cell death raises an unanswered question about cancer surveillance and tissue homeostasis, and there is no human pharmacovigilance to characterize whether that matters in practice. Long-term effects, drug interactions, and organ-level effects in humans are simply unknown. Nothing here is medical advice.

Bottom line

Humanin sits on a genuinely interesting biological foundation — the first mitochondrial-derived peptide, a coherent cytoprotective mechanism, and consistent signals in cells and animals — and a near-empty one in humans. Every human study to date is observational or correlational; no one has been given humanin in a trial, and its human safety is uncharacterized. It is an unapproved, research-grade compound that should be treated as high-risk in sport. Anyone using injected humanin as a proven longevity, brain, or recovery therapy is far ahead of the evidence.

Evidence grade: Animal only.